MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

MDT

88.96

+0.59%ā†‘

VEEV

226.47

-0.52%ā†“

A

115.98

+2.05%ā†‘

HQY

88.73

+1.89%ā†‘

PDCO

31.27

+0.06%ā†‘

Search

Vivani Medical

Gesloten

1.01 1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.98

Max

1.01

Belangrijke statistieken

By Trading Economics

Werknemers

36

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+292.16% upside

Dividenden

By Dow Jones

Volgende Winsten

9 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

61M

Vorige openingsprijs

0.01

Vorige sluitingsprijs

1.01

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jun 2024, 15:28 UTC

Belangrijke Marktbewegers

Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

292.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4Ā USDĀ  292.16%

Hoogste 4Ā USD

Laagste 4Ā USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Financieel

$

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.